zacks.com · 23 jun

DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?

DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.

newsfilecorp.com · 22 jun

Focus Graphite Announces SEDAR+ Filing of the NI 43-101 Technical Report with the Updated Mineral Resource for the Lac Tetepisca Project

One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce that it has filed the report on SEDAR+ for the upgraded mineral resource estimate ("MRE") on its 100%-owned Lac Tetepisca Project (the "Project") in Quebec. The Project lies within the Nitassinan (ancestral land) of the Pessamit Innu First Nation of Betsiamites, Quebec.

newsfilecorp.com · 15 jun

Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting

Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the Hydrogeological Assessment (the "Assessment" or the "Study") for its wholly-owned Lac Knife Graphite Project ("Lac Knife" or the "Project"), concluding a multi-year environmental program and completing the major technical work required to support the Company's Environmental and Social Impact Assessment ("ESIA") submission. Completed by Yves Leblanc, P.Geo.

zacks.com · 8 jun

FMS and Home Dialysis: How 5008X Could Reset Demand

FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.

zacks.com · 5 jun

FMS Launches kinexus Digital Platform for Home Dialysis Care

Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.

prnewswire.com · 3 jun

Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis

Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programs Designed to simplify care processes for healthcare teams and their patients to support high-quality, personalized care for patients dialyzing at home Enables managing peritoneal dialysis and home hemodialysis therapies across Fresenius Medical Care's global home dialysis portfolio in one digital platform BAD HOMBURG, Germany, June 3, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the global launch of kinexus, a unified digital platform designed to support home dialysis programs and strengthen connected, patient-centered care. With kinexus, Fresenius Medical Care (FME) is advancing connected home dialysis care by bringing together digital modules supporting peritoneal dialysis (PD) and home hemodialysis (HHD) within a single, unified platform.

prnewswire.com · 28 may

Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million

BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1 billion. The first tranche, amounting up to EUR 600 million, was initiated today and is expected to be completed by December 15, 2026.

prnewswire.com · 27 may

Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026

Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalization New research focuses on applying real-world evidence, patient-centered outcomes and artificial intelligence across dialysis modalities and continuity of kidney care A preview of kinexus, a unified digital platform intended to support home dialysis programs by connecting therapy management and care workflows BAD HOMBURG, Germany, May 27, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, presents new research highlighting ongoing innovation at the European Renal Association (ERA) Congress 2026, June 3-6 in Glasgow, Scotland, and virtually. The Company highlights advancements including new hemodiafiltration research that reaffirm its leadership in evidence based and personalized dialysis care, real-world evidence to strengthen patient centered outcomes across dialysis modalities, and the application of artificial intelligence (AI) to improve patient outcomes.